Combination treatment for small cell lung cancer after immunotherapy
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two drugs, adebrelimab and irinotecan liposome, with or without a third drug called famitinib, for people with extensive-stage small cell lung cancer that has progressed after initial treatment with immunotherapy. The goal is to see if this combination can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have extensive-stage small cell lung cancer that has grown or spread after at least one line of treatment that included immunotherapy.
- You have not had more than two prior lines of chemotherapy.
- You have not been treated with drugs called topoisomerase I inhibitors (like irinotecan or topotecan) before.
- You have not been treated with certain anti-angiogenesis drugs (like bevacizumab, anlotinib, or apatinib) before.
- You have not had active brain metastases or certain other serious conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—an immunotherapy (adebrelimab), a targeted therapy (famitinib), and chemotherapy—for people with extensive-stage small cell lung cancer. The goal is to see if this triple combination works better than standard treatment.
This trial tests a new combination of an immunotherapy drug (adebelimab) with chemotherapy as a first treatment for extensive-stage small cell lung cancer. It aims to see if this combination can help control the cancer better than standard care.
This trial tests a combination of immunotherapy (adebrelimab), chemotherapy, and targeted radiation (SBRT) before surgery for people with limited-stage small cell lung cancer. The goal is to see if this approach can shrink tumors and improve outcomes before the main treatment.
This trial tests a combination of immunotherapy (adebrelimab), a targeted therapy (apatinib), and chemotherapy given before surgery for people with limited-stage small cell lung cancer. The goal is to see if this treatment shrinks the tumor enough to make surgery more effective and to study markers that might predict response.
This study tests a new combination treatment for extensive-stage small cell lung cancer. You would receive an immunotherapy drug (adebrelimab) together with chemotherapy and a very low dose of chest radiation, to see if this helps control the cancer better.
This trial tests a combination of irinotecan liposome (a chemotherapy) or etoposide with adebrelimab (an immunotherapy) and carboplatin for people with extensive-stage small cell lung cancer who haven't had prior treatment. It aims to see if these combinations are safe and effective.
Hear when a new Small Cell Lung Cancer Extensive Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.